BellaSeno Appoints New Chief Technology Officer and VP Quality and Regulatory Affairs

Medtech company, BellaSeno has appointed Dr. Thomas Lingner as Chief Technology Officer and promoted Inga Freyert to Vice President of Quality and Regulatory Affairs. 
 
Currently, Lingner also serves as Managing Director and CSO to a bioinformatics/software company he co-founded called Genevention GmbH. Lingner previously served as Principal Bioinformatician, Microarray and Deep-Sequencing Core Facility, at the University Medical Center Göttingen. He also worked at the University of Göttingen, CRG Barcelona, Spain, and the University of Stavanger, Norway as a post-doctoral researcher. 
 
Since 2022, Freyert served as head of quality management at BellaSeno, and was promoted to VP of Quality Management and Regulatory Affairs early in 2024. Before BellaSeno, Freyert served as the Head of Quality Management at TimeWaver Production GmnH. She also served at bess pro GmbH as a quality management representative, MagForce AG, Berlin as the Quality & Regulatory Specialist / Junior Q&R Manager, and she was Head of Batch Record Review Quality Control Team at IDT Biologika GmbH, Dessau-Roßlau.
 
“We warmly welcome Dr. Thomas Lingner and Inga Freyert to their new roles at BellaSeno,” said BellaSeno CEO, Dr, Mohit Chhaya. “Top-tier quality standards and technological leadership are at the heart of BellaSeno ́s corporate identity. Therefore, the expertise of Thomas and Inga will be crucial for further advancing our leading-edge pipeline in soft and hard tissue regeneration.”